MYRIAD GENETICS AND BAYER CORPORATION EXTEND PROTEOMICS COLLABORATION THROUGH DECEMBER 31,2002
Alliance Expanded Into Obesity in Addition to Dementia Pathways
21-Dec-2000 -
Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it
has extended its proteomics collaboration with Bayer
Corporation through December 31, 2002. This highly productive
research program, using Myriad's ProNet® technology, has
already discovered six candidate therapeutic targets in
...
Bayer
dementia
medicine
+2